Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and nine months ended September 30, 2021
Business Overview: The world's leading provider of products and services for individuals with renal diseases, operating a vertically integrated business model comprising dialysis care services and the manufacturing/distribution of health care products (hemodialysis machines, dialyzers, pharmaceuticals). The company operates in four geographic segments: North America, EMEA, Asia-Pacific, and Latin America.
Key Financial Metrics (Nine Months Ended Sept 30, 2021)
| Metric | 2021 (€M) | 2020 (€M) | Change |
|---|---|---|---|
| Total Revenue | 12,972 | 13,459 | (4%) |
| Operating Income | 1,403 | 1,843 | (24%) |
| Net Income (Shareholders) | 741 | 987 | (25%) |
| Operating Margin | 10.8% | 13.7% | -290 bps |
| Free Cash Flow | 1,259 | 2,913 | (57%) |
| Net Debt | 11,665 | 11,298 | +3% |
| Net Leverage Ratio | 3.1x | 2.7x | +0.4x |
Note: Revenue and operating income decreased primarily due to foreign currency translation effects and the absence of U.S. federal relief funding (CARES Act) received in the prior year. At constant currency, revenue increased by 2% and operating income decreased by 20%.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue fell 4% year-over-year. Health care services revenue decreased 4% (driven by a 6% negative currency impact), while health care products revenue decreased 1%. At constant currency, both categories grew (2% and 2% respectively).
- Profitability Compression: Operating income dropped 24% (20% at constant currency). Gross profit declined 10% due to inflationary cost increases, higher personnel expenses, and the expiration of U.S. government relief payments. SG&A expenses increased 2% (7% at constant currency) due to cloud computing costs, bad debt, and transformation program costs.
- COVID-19 Impact: The pandemic reduced net income attributable to shareholders by €262 million for the nine-month period, primarily due to excess patient mortality and the cessation of government relief funds. Same Market Treatment Growth was negative 1.9%.
- Segment Performance:
- North America: Revenue flat at constant currency; Operating income down 17% (constant currency) due to cost inflation and lack of CARES Act funding.
- EMEA: Revenue flat at constant currency; Operating income down 16% (constant currency) due to inflation and product mix.
- Asia-Pacific: Revenue up 8% (constant currency); Operating income up 10% (constant currency) driven by recovery in elective procedures.
- Latin America: Revenue up 16% (constant currency); Operating income down 54% (constant currency) due to inflation and bad debt.
Guidance, Outlook, and Risks
- Strategic Transformation (FME25): Announced on November 2, 2021, a program to reorganize the business into two global operating segments (Health Care Products and Health Care Services) to strengthen profitability. Implementation expected by 2023.
- Reimbursement Risks: Significant exposure to U.S. Medicare reimbursement rates. The ESRD PPS base rate for 2022 increased 1.9%. The company faces uncertainty regarding the ESRD Treatment Choices (ETC) model and voluntary Kidney Care First models, which could impact future revenue and costs.
- Legal and Regulatory: Ongoing compliance with a non-prosecution agreement (NPA) with the DOJ and SEC regarding FCPA violations (monitorship expected to conclude in 2022). Various False Claims Act investigations and patent litigation (e.g., Velphoro) remain pending.
- Liquidity: The company maintains a €2.0 billion syndicated credit facility (undrawn) and a €1.5 billion commercial paper program. Net leverage ratio increased to 3.1x, driven by lower adjusted EBITDA.
Investor Verification Checklist
- CARES Act Recoupment: Verify the timing and impact of the recoupment of advanced Medicare payments received in 2020, which significantly reduced 2021 operating cash flow.
- Constant Currency Adjustments: Scrutinize the difference between reported and constant currency growth to assess underlying operational performance versus currency headwinds.
- Reimbursement Rate Changes: Monitor the final implementation details of the 2022 ESRD PPS rate and the ETC model to assess long-term margin pressure in the North America segment.
- Latin America Impairment: Review the specific drivers of the 54% operating income decline in Latin America, particularly regarding inflation and bad debt provisions.
- Transformation Costs: Track the costs associated with the new FME25 operating model and its impact on future SG&A expenses.